ACAAI 2022

Conference Coverage

Mepolizumab Shows Real-World Efficacy in Allergic and Non-Allergic Asthma

Exacerbations Risk Exists for Patients With All Levels of Asthma Control/Severity

Azelastine HCI 0.15% Nasal Spray Rapidly Relieves Seasonal Allergy Symptoms

Researchers Link Smell Loss, Disease Burden, and Dupilumab Efficacy in CRSwNP

Use of Biologics Reduces Exacerbations, Emergency Visits in Pediatric Asthma

Allergen Exposure, Other Factors Predict Limited Airflow in Pediatric Asthma

Certain Clinical Markers May Predict AERD in Patients With CRSwNP

Uncontrolled Asthma in Hispanic/Latino Patients Improved With Tezepelumab

Early Atopic Dermatitis Modifies the Risk for Allergic Respiratory Disease

Safety of Lebrikizumab Similar to Placebo in Patients With Uncontrolled Asthma

Epicutaneous Immunotherapy Safe, Effective in Toddlers With Peanut Allergy

Maintenance and Reliever Digital System vs Standard Care Improves Asthma Control

Asthma Exacerbations and Systemic Corticosteroid Use Reduced With Dupilumab

Exhalation Delivery System With Fluticasone Improves Sinusitis Without Polyps

Needle-Free Epinephrine Delivery Would Lead to Faster Allergy Response

Number of Patient-Reported Severe Asthma Triggers Predicts Morbidity

Lanadelumab Significantly Lowers Hereditary Angioedema Attacks vs Berotralstat